» Articles » PMID: 39744682

Engineering Nanosystems for Regulating Reproductive Health in Women

Overview
Journal Theranostics
Date 2025 Jan 2
PMID 39744682
Authors
Affiliations
Soon will be listed here.
Abstract

Reproductive health-related diseases have a significant impact on the well-being of millions of women worldwide, severely compromising their quality of life. Women encounter unique challenges in terms of reproductive health, including gynecological diseases and malignant neoplasms prior to pregnancy, as well as complications during pregnancy that greatly undermine their physical and mental health. Despite recent advancements in the field of female reproduction, substantial challenges still persist. To address these challenges, nanotechnology-based diagnostic and therapeutic strategies have emerged to provide intelligent detection and treatment for pathologies related to women's reproductive health. Although some progress has been made with nanotherapeutics in this domain, its application is still nascent due to the delicate and intricate nature of the female reproductive system. This review comprehensively presents the latest advancements in nanomedicine for regulating woman's reproductive health. Firstly, based on the time period of onset, nanomedicine applications are categorized into four subcategories: 1) preconception diseases such as polycystic ovary syndrome, endometriosis, and gynecologic malignancy treatment; 2) pregastrulation period diseases including placenta accreta spectrum disorders and ectopic pregnancy; 3) mid-term pregnancy diseases like preeclampsia; and 4) late pregnancy diseases such as deep vein thrombosis during pregnancy. The systematic introduction covers the progress made by nanomedicine in various disease areas. Finally, this article discusses the challenges faced by these nanomedicines from research to clinical translation while also highlighting future directions.

References
1.
Cheng J, Zhang S, Li C, Li K, Jia X, Wei Q . Functionally integrating nanoparticles alleviate deep vein thrombosis in pregnancy and rescue intrauterine growth restriction. Nat Commun. 2022; 13(1):7166. PMC: 9684510. DOI: 10.1038/s41467-022-34878-2. View

2.
Fu Q, Li Z, Fu F, Chen X, Song J, Yang H . Stimuli-Responsive Plasmonic Assemblies and Their Biomedical Applications. Nano Today. 2020; 36. PMC: 7687854. DOI: 10.1016/j.nantod.2020.101014. View

3.
Lin S, Lee H, Hsu C, Huang Y, Li W, Hsu P . Targeting Anthrax Toxin Receptor 2 Ameliorates Endometriosis Progression. Theranostics. 2019; 9(3):620-632. PMC: 6376465. DOI: 10.7150/thno.30655. View

4.
Chen X, Koivuaho E, Piltonen T, Gissler M, Lavebratt C . Association of maternal polycystic ovary syndrome or anovulatory infertility with obesity and diabetes in offspring: a population-based cohort study. Hum Reprod. 2021; 36(8):2345-2357. PMC: 8289324. DOI: 10.1093/humrep/deab112. View

5.
Azziz R, Carmina E, Chen Z, Dunaif A, Laven J, Legro R . Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2:16057. DOI: 10.1038/nrdp.2016.57. View